The Cavalier Daily

Brian Wamhoff discusses goals for Manning Institute as chief strategy and business officer

The Paul and Diane Manning Institute of Biotechnology announced June 16 that Brian Wamhoff, current public director of the ...
Las Vegas Sun

Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies

Jul 16, 2026-- Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a nex ...